Latest news about EIKO Lifesciences
EIKO Lifesciences
47.02
0.00(0.00%)
Company Performance:
View Company Insights1D0.00%
1M-6.17%
6M-10.44%
1Y-11.18%
5Y-53.14%
More news about EIKO Lifesciences
10Apr 26
Eiko Lifesciences Limited Confirms Non-Applicability of SEBI Large Corporate Debt Framework
Eiko Lifesciences Limited has informed BSE Limited that it does not qualify as a Large Corporate under SEBI criteria as of March 31, 2026. This status exempts the company from the regulatory framework governing debt securities issuance by large corporates, eliminating the requirement for initial and annual disclosures under SEBI Circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018.
26Feb 26
Eiko Lifesciences: Promoter Bhavesh Tanna Acquires 3.14% Stake via Preferential Issue
Eiko Lifesciences completed a preferential allotment where promoter Bhavesh Dhirajlal Tanna acquired 4,50,000 equity shares representing 3.14% stake and 15,50,000 warrants at Rs. 55 per share. His total holding increased from 2.84% to 5.86% on non-diluted basis, with potential to reach 13.82% upon warrant conversion. The company's share capital increased to Rs. 14,34,58,540 post-allotment.
09Jan 26
Eiko LifeSciences Shareholders Approve Preferential Issuance of Warrants and Equity Shares
Eiko LifeSciences Limited conducted its first Extra-Ordinary General Meeting on January 7, 2026, where shareholders approved two special resolutions with 99.9999% support. The resolutions authorized issuance of 33,00,000 warrants convertible into equity shares and 6,75,000 equity shares on preferential basis to promoter and public categories. The meeting was held via video conferencing with 21 shareholders participating, and voting was conducted through remote e-voting and during the meeting, demonstrating strong stakeholder support for the company's capital raising initiatives.
05Jan 26
Eiko LifeSciences Promoter Group Entity Penalized ₹1.00 Lakh by SEBI for Regulatory Non-Compliance
Eiko LifeSciences disclosed that SEBI imposed a ₹1.00 lakh penalty on its promoter group entity M/s. Lenus Finvest Private Limited for alleged non-compliance with SAST regulations during November 2019 to June 2021. The violation specifically relates to non-disclosure of margin pledge requirements, but the company confirmed no material impact on its financial operations or business activities. The promoter group entity plans to explore legal options to challenge the adjudication order.
12Dec 25
Eiko Life Sciences EGM for ₹21.86 cr fundraise
EIKO Lifesciences Limited has scheduled an EGM for January 7, 2026, to seek approval for a ₹21.86 crore fundraising initiative through preferential allotment. The plan includes issuing 33,00,000 warrants and 6,75,000 equity shares at ₹55 each. The primary objective is to acquire a majority stake in SSM Formulations Private Limited, allocating ₹14.44 crores for this purpose. The fundraising involves both promoter and non-promoter participation, with strategic goals of portfolio expansion and market entry.
12Dec 25
Eiko Lifesciences Acquires 51% Stake in WHO-GMP Accredited SSM Formulations
EIKO Lifesciences Limited has agreed to acquire a 51% equity stake in SSM Formulations Private Limited for ₹18 crores. SSM Formulations is a WHO-GMP accredited pharmaceutical formulations company based in Hinganghat, Wardha. The acquisition expands EIKO's capabilities from specialty chemicals and API supplier to a fully integrated pharmaceutical player. SSM brings high-barrier capabilities including Narcotics License, international registrations, and a strong manufacturing base. EIKO plans to raise funds through warrants and equity shares to support the acquisition and growth plans.
31Oct 25
Eiko Life Sciences Reports 281% Surge in Q2 Profit, Revenue Up 19%
EIKO Lifesciences, a specialty chemicals and pharma intermediates company, announced impressive Q2 FY2026 results. Net profit soared 281% year-on-year to ₹81.76 lakhs, while revenue from operations grew 19% to ₹919.74 lakhs. Earnings per share increased by 275% to ₹0.60. Half-year profit rose 172% to ₹150.98 lakhs. Consolidated results showed even stronger performance with a 43% revenue increase and 356% net profit growth. The Board approved these unaudited results on October 31, 2025.
29Jul 25
Eiko LifeSciences Reports Strong Q1 Results, Announces Board Changes and Capital Increase
Eiko LifeSciences Limited reported its Q1 FY2025-26 results. Consolidated revenue was ₹1,071.15 lakhs, slightly down from ₹1,075.04 lakhs in Q1 last year. However, profit after tax significantly increased to ₹111.74 lakhs from ₹37.13 lakhs. EPS rose to ₹0.66 from ₹0.29. The company announced board changes including the resignation of Mr. Umesh More and appointment of Mr. Sumukh Prabhakar Vartak as Whole Time Director. The board approved an increase in authorized share capital from ₹14 crore to ₹20 crore, subject to shareholder approval. The company operates in specialty chemicals and logistics segments, with the former contributing ₹840.22 lakhs in revenue and the latter ₹230.93 lakhs.
29Jul 25
Eiko LifeSciences Announces Board Changes and Expansion Plans at 48th AGM
Eiko LifeSciences Limited has announced significant board changes including the resignation of Mr. Umesh More and appointment of Mr. Sumukh Prabhakar Vartak as Whole Time Director. The company plans to increase its Authorized Share Capital from Rs. 14 crore to Rs. 20 crore. For Q1 FY 2025-26, the company reported a consolidated net profit of Rs. 111.74 lakhs, up from Rs. 37.13 lakhs in the same quarter last year. The 48th AGM is scheduled for September 5, 2025, where these changes and financial results will be addressed.
Industry Peers
Pidilite Industries
SRF
Gujarat Fluorochemicals
Navin Fluorine International
Deepak Nitrite
Aether Industries
Aarti Industries
Atul
BASF
Fine Organic Industries
1,660.00
(+0.67%)
2,580.80
(+0.35%)
4,622.60
(+0.02%)
8,187.00
(-0.24%)
1,730.30
(-0.96%)
1,667.80
(+2.53%)
543.15
(+3.03%)
6,425.00
(-1.30%)
3,878.60
(-0.62%)
5,277.40
(+2.28%)
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
